FMP
Adverum Biotechnologies, Inc.
ADVM
NASDAQ
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
3.33 USD
0.07 (2.1%)
Historical Prices
From:
To:
About
ceo
Dr. Laurent Fischer
sector
Healthcare
industry
Biotechnology
website
https://www.adverum.comexchange
NASDAQ
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...
CIK
0001501756
ISIN
US00773U1088
CUSIP
00773U108
Address
800 Saginaw Drive
Phone
650 656 9323
Country
US
Employee
155
IPO Date
Jul 31, 2014
Financial Statement
Earnings
ADVM Financial Summary
CIK
0001501756
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00773U108
ISIN
US00773U1088
Country
US
Price
3.33
Beta
1.09
Volume Avg.
253.94k
Market Cap
69.57M
Shares
-
52-Week
2.64-10.84
DCF
-1.63
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.5
P/B
-
Website
https://www.adverum.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ADVM News
Danny Green
Apr 3, 2025
Adverum Biotechnologies Faces Investigation and Financial Re...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is under scrutiny as Pomerantz LLP investigates potential securities fraud or other unlawful practices. This follows Adverum's disclosure of unreliable financial statements due to non-cash errors related to tenant improvement allowances. The company plans to restate its financials for 2022, 2023, and quarterly data for 2023 and 2024. This announcement led to a 12.36% drop in ADVM's stock price, closing at $3.83 on April 1, 2025. Despite the investigat...
Stuart Mooney
Apr 2, 2025
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Faces Scrutiny A...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a biotechnology company focused on developing gene therapies for ocular and rare diseases. On April 2, 2025, Leonard Braden Michael, a significant shareholder with a 10% stake, purchased 15,209 shares of ADVM at $4.04 each. This acquisition increased his total ownership to 2,757,526 shares, reflecting confidence in the company's potential. Despite this insider purchase, Adverum faces scrutiny as Levi & Korsinsky investigates potential federal secur...
GlobeNewsWire
Aug 2, 2024
Adverum Biotechnologies to Participate in the H.C. Wainwrigh...
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 2:00 p.m. ET.
Zacks Investment Research
Jul 18, 2024
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medica...
Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.
Seeking Alpha
Jul 17, 2024
Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analys...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM ) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 8:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - President & CEO Charles Wykoff - Director of Research, Retina Consultants of Texas Conference Call Participants Joon Lee - Truist Securities Joseph Thome - TD Cowen Francois Brisebois - Oppenheimer Graig Suvannavejh - Mizuho Securities Luca Issi - RBC Capital Daniil Gataulin - Chardan Operator Hello, l...
Zacks Investment Research
Jul 16, 2024
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Co...
The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research
May 10, 2024
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the D...
Adverum Biotechnologies (ADVM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewsWire
May 3, 2024
Adverum Biotechnologies to Participate in Upcoming May Inves...
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences:
